|  |
| --- |
| November 28, 2017Press Contact Dr. Jürgen KrauterHead of CommunicationsNutrition & CarePhone +49 6181 59-6847Fax +49 6181 59-76847juergen.krauter@evonik.com |
| Specialized Press ContactChristian FürstenauHead of CommunicationsInterface & PerformancePhone +49 201 173-2019Fax +49 201 173-712019christian.fuerstenau@evonik.com |

Evonik Nutrition & Care GmbH

Rellinghauser Straße 1-11

45128 Essen

Germany

Telefone +49 201 177-01

Fax +49 201 177-3475

www.evonik.com

**Supervisory Board**

Dr. Harald Schwager, Chairman

**Managing Directors**

Dr. Reiner Beste, Chairman

Dr. Hans Josef Ritzert

Michael Gattermann

Markus Schäfer

Registered office Essen

Registered court

Essen local court

Commercial registry B 25784

HR no. FN 431387 v

**Evonik to acquire high-concentrates additive compounding business from 3M**

* Expanded specialty additives for plastics industry product portfolio now includes solid additives
* Access to key technology enables innovative solutions for the plastics industry
* Acquisition underlines growth focus in Specialty Additives - one of Evonik’s growth engines

Essen, Germany. Specialty chemicals company Evonik is to acquire 3M’s high-concentrates additive compounding business, and the corresponding agreement has been signed. The specialty chemicals group is further expanding its capabilities in the highly profitablebusiness with specialty additives. Evonik already offers a variety of additives to the plastics industry, and the acquisition will enable the company to now also offer solid additives.

Dr. Dietmar Schaefer, Head of Evonik’s Interface & Performance Business Line, states: “We are gaining an excellent platform for the development of innovative solutions, and will be able to significantly expand our product portfolio with this acquisition.” The transaction enhances the enterprise’s capabilities in specialty additives – one of its key areas of business growth. The transaction is expected to close in the first quarter 2018, subject to the customary closing conditions. The parties have agreed not to disclose the price of the purchase.

The deal includes the Accurel® brand product portfolio which is produced in Obernburg (Bavaria, Germany) as well as the Obernburg production facility with approximately 25 jobs which will be retained. The high-concentrates additive compounding technology allows plastic manufacturers to introduce large volumes of additives into a polymer matrix via a solid polymer carrier. This will enable Evonik to target new applications, for instance the packaging industry. These operations are to be incorporated into Evonik’s Interface & Performance Business Line.

The Business Line produces and markets specialty additives for the plastics industry. These either improve the processing of plastics, e.g. by better filler dispersion, improved flow, or enhance the performance (improved scratch-resistance, controlled odor and improved mechanical strength). In addition, Interface & Performance leverages innovative technology platforms for the production of silicones and specialty additives based on surfactants. Typical applications that the company is addressing within the plastics industry with specialty additives include films, foams, fibers, nonwoven fabrics, injection molding and cables.

**About Evonik**

Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-orientated innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 36,000 employees. In fiscal 2016, the enterprise generated sales of around €12.7 billion and an operating profit (adjusted EBITDA) of about €2.165 billion.

**About Nutrition & Care**

The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 7,500 employees, and generated sales of around
€4.3 billion in 2016.

**Disclaimer**

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.